• 1
    Whelton PK. Epidemiology of Hypertension. Lancet. 1994;344:101106.
  • 2
    McMahon S, Peto R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease, part I: prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765774.
  • 3
    Collins R, Petro R, MacMahon S, et al. Blood pressure, stroke, and coronary heart disease, part II: short-term reductions in blood pressure: overview of randomized clinical trials in their epidemiological context. Lancet. 1990;335:827838.
  • 4
    Whelton PK, Perneger TV, Klag MJ, et al. Epidemiology of blood pressure-related renal disease. J Hypertens. 1992;10(suppl 7):S77S84.
  • 5
    Stamler J, Stamler R, Neaton JD. Blood pressure, systolic and diastolic and cardiovascular risks: U. S. population data. Arch Intern Med. 1993;153:598615.
  • 6
    Messeri P, Workman S, Saunders C, et al. The application of meta-analysis in assessing racial differences in the effects of antihypertensive medication. J. Nat Med Assn. 1997;89:477485.
  • 7
    Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA. 1998;279(23): 19031907.
  • 8
    Nelsen LM, Himmelberger DU, Morrison A, et al. Quality-of-life questionnaire for patients taking antihypertensive medication. Clin Ther. 1999;21(10):17711787.
  • 9
    Moser M. The cost of treating hypertension: can we keep it under control without compromising level of care? Am J. Hypertens. 1998;11(8 pt 2):S120S127.
  • 10
    Mancia G, Dell-Oro R, Turri C, et al. Comparison of angiotensin II receptor blockers: impact of missed doses of candesartan cilexetil and losartan in systemic hypertension. Am J Cardiol. 1999;84(10A):28S34S.
  • 11
    Wilson TW, Lacourciere Yves, Barnes CC. The antihypertensive efficacy of losartan and amlodipine assessed with office and ambulatory blood pressure monitoring. CMAJ. 1998;159(5):469476.
  • 12
    The sixth report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Arch Intern Med. 1997;157(21): 24132446.
  • 13
    Hansson L, Zansson L, Zanchetti A, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomized trial. HOT Study Group. Lancet. 1998;351:17551762.
  • 14
    Staessen J, Thijs L, Gasowski J, et al., for the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Treatment of isolated systolic hypertension in the elderly: further evidence from the Systolic Hypertension in Europe (Syst-Eur) Trial. Am J Cardiol. 1998;82:20R22R.
  • 15
    Hansson L, Lindholm LH, Ekbom T, et al., For the STOP-Hypertension-2 study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet. 1999;354: 17511756.
  • 16
    Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomized to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet. 2000;356:366372.
  • 17
    Hansson L, Hedner T, Lund-Johansen P, et al. Randomised trial of effects of calcium antagonists compared with diuretics and β-blockers on cardiovascular morbidity and mortality in hypertension: the Nordic Diltiazem (NORDIL) study. Lancet. 2000;356:359365.
  • 18
    Parati G, Ravogli A, Frattola A, et al. Blood pressure variability: clinical implications and effects of antihypertensive treatment. J Hypertens Suppl. 1994;12(5):S35S40.
  • 19
    Millar-Craig MW, Vishop CN, Rafferty EB. Circadian variation of blood pressure. Lancet. 1978;I:795797.
  • 20
    Ackermann RJ, Meyer von Bremen GB. Reducing polypharmacy in the nursing home: an activist approach. Am Board Fam Pract. 1995;8(3):195205.
  • 21
    Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001;345:851860.
  • 22
    Agadoa LY, Appel L, Bakris GL, et al., for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA. 2001;285:27192728.
  • 23
    Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med. 2001;345:861869.
  • 24
    Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. Irbesartan Briefing Document. Rockville , MD : National Press Office; January 7, 2002.
  • 25
    Dahlof B, Devereux RB, Kjeldsen SE, et al., for the LIFE study group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomized trial against atenolol. Lancet. 2002;359:9951003.
  • 26
    The ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs. chlorthalidone: The Antihypertensive and Lipid-Lowering Treatment to prevent Heart Attack Trial (ALLHAT). JAMA. 2000;283: 19671975.